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a b s t r a c t
Adaptation to low oxygen tension (hypoxia) is a critical event during development. The transcription
factors Hypoxia Inducible Factor-1α (HIF-1α) and HIF-2α are essential mediators of the homeostatic
responses that allow hypoxic cells to survive and differentiate. Von Hippel–Lindau protein (VHL) is the
E3 ubiquitin ligase that targets HIFs to the proteasome for degradation in normoxia. We have previously
demonstrated that the transcription factor HIF-1α is essential for survival and differentiation of growth
plate chondrocytes, whereas HIF-2α is not necessary for fetal growth plate development. We have also
shown that VHL is important for endochondral bone development, since loss of VHL in chondrocytes
causes severe dwarﬁsm. In this study, in order to expand our understanding of the role of VHL in
chondrogenesis, we conditionally deleted VHL in mesenchymal progenitors of the limb bud, i.e. in cells
not yet committed to the chondrocyte lineage. Deﬁciency of VHL in limb bud mesenchyme does not alter
the timely differentiation of mesenchymal cells into chondrocytes. However, it causes structural collapse
of the cartilaginous growth plate as a result of impaired proliferation, delayed terminal differentiation,
and ectopic death of chondrocytes. This phenotype is associated to delayed replacement of cartilage by
bone. Notably, loss of HIF-2α fully rescues the late formation of the bone marrow cavity in VHL mutant
mice, though it does not affect any other detectable abnormality of the VHL mutant growth plates. Our
ﬁndings demonstrate that VHL regulates bone morphogenesis as its loss considerably alters size, shape
and overall development of the skeletal elements.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The ability of a cell to adapt to low oxygen tension (hypoxia) is
critical both in pathological settings such as cancer and ischemia,
and in normal development and differentiation (Maes et al., 2012).
The transcription factors Hypoxia Inducible Factor-1α (HIF-1α)
and HIF-2α are crucial mediators of the homeostatic responses
that allow hypoxic cells to survive and differentiate (Dunwoodie
2009). These proteins trigger a range of autonomous, autocrine,
paracrine and endocrine effects with the overall goal of increasing
oxygen delivery to tissues while decreasing their oxygen con-
sumption, and thus promoting cell survival and differentiation
(Rankin and Giaccia, 2008; Semenza, 2009, 2012).
HIF is a heterodimeric protein that results from the association
between HIF-α and HIF-β subunits (Wang et al., 1995). Three
distinct forms of HIF-α and HIF-β do exist, and they are each the
product of distinct paralogue genes (Hirose et al., 1996; Takahata
et al., 1998). Each alpha subunit is able to bind any of the beta
subunit to form a functional transcription factor. The beta
subunit is constitutively expressed, whereas the alpha subunit is
the oxygen-regulated element of the complex. In normoxia,
a family of HIF prolyl-4-hydroxylases (PHDs) is responsible for
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the hydroxylation of two proline residues (P402 and P564) in the
oxygen dependent degradation domain of HIF-1α (Ivan et al.,
2001; Jaakkola et al., 2001). The E3 ubiquitin ligase von Hippel–
Lindau (VHL) binds to the hydroxylated HIF-1α, and targets it to
the proteasome for degradation (Ivan et al., 2001; Maxwell et al.,
1999). In hypoxia, hydroxylation of HIF-1α is inefﬁcient, and thus
HIF-1αmigrates to the nucleus, binds HIF-1β, and hence promotes
transcription of genes that have hypoxia responsive elements in
their promoter region. The HIF-2α isoform is regulated by oxygen
with a modality similar to HIF-1α (Keith et al., 2011).
The importance of VHL for proteolysis of HIF-1α and HIF-2α is
highlighted by the ﬁnding that cells lacking functional VHL are
unable to degrade these transcription factors, ultimately resulting
in their accumulation (Ivan et al., 2001; Maxwell et al., 1999;
Haase, 2005; Kamura et al., 2000). However, VHL has also a variety
of biological activities including control of the cell cycle, regulation
of matrix proteins, interaction with the cytoskeleton and with the
primary cilia that are HIF-independent (Hsu, 2012; Kaelin, 2008).
The fetal growth plate is a suitable model to study cellular
adaptation to hypoxia during development (Provot and Schipani,
2007). Bone can form through two different mechanisms, intra-
membranous and endochondral. While the ﬂat bones of the skull
develop from mesenchymal cells that directly differentiate into
osteoblasts (intramembranous bone formation), the other skeletal
elements derive from a chondrocyte anlage that is replaced by
bone (Karsenty, 2003; Kronenberg, 2003; Lefebvre and Smits,
2005; Provot and Schipani, 2005). This latter process is called
endochondral bone development.
During endochondral bone development, mesenchymal cells
ﬁrst condense; cells within these condensations next differentiate
into chondrocytes and generate the fetal growth plate. Growth
plate chondrocytes are highly proliferative, and while they divide,
they also pile up to form a columnar layer. The most distal cells of
the columnar layer stop proliferating, exit the cell cycle, and
differentiate into hypertrophic chondrocytes, which mineralize
their surrounding matrix. The cartilaginous mold is then invaded
by blood vessels and replaced by bone at two sites, the primary
spongiosa and the secondary ossiﬁcation center, respectively
(Kronenberg, 2003; Gerber et al., 1999; Zelzer and Olsen, 2005).
In parallel to the chondrocyte differentiation process, three-
layered interzones that will give origin to the prospective synovial
joints are speciﬁed; formation of the synovial space occurs upon
cavitation of these interzones (Khan et al., 2007; Craig et al., 1987).
Consistent with its avascularity, the murine fetal growth plate
displays a gradient of oxygenation with an inner, hypoxic region
(Schipani et al., 2001).
The VHL/HIF pathway impacts numerous aspects of cartilage
and bone biology. In particular, during growth plate development,
HIF-1α is required for timely differentiation of mesenchymal cells
into chondrocytes, for chondrocyte survival and for joint speciﬁca-
tion (Schipani et al., 2001; Provot et al., 2007). Therefore, this
transcription factor is necessary for endochondral bone develop-
ment. Conversely, HIF-2α is virtually dispensable, as deﬁciency of
HIF-2α causes only a modest and transient delay of chondrocyte
terminal differentiation (Araldi et al., 2011).
We have also recently reported an important role of VHL in
endochondral bone development (Pfander et al., 2004). Mice
lacking VHL in chondrocytes display a striking growth plate
phenotype characterized by hypocellularity, impaired prolifera-
tion, and increased cell size in the round proliferative zone. These
features eventually lead to severe dwarﬁsm. Notably, loss of both
VHL and HIF-1α in chondrocytes causes a growth plate phenotype
identical to the one described in HIF-1α null animals (Schipani
et al., 2001); HIF-1α is thus epistatic to VHL.
In order to better understand the role of VHL in the early steps
of chondrogenesis, we genetically deleted VHL in mesenchymal
progenitors of the limb bud, i.e., in cells that will give origin to the
cartilage anlage by differentiating into chondrocytes but are not
yet committed to the chondrocyte lineage. Our ﬁndings demon-
strate that loss of VHL in limb bud mesenchyme alters multiple
steps of endochondral bone development and, thus, they provide
clear evidence that VHL is a crucial regulator of this process.
Materials and methods
All the experiments were performed using at least three
independent biological replicates.
Generation of mice
Generation and genotyping of the VHL (FVB/N), HIF-1α (FVB/N)
and HIF-2α (C57/B6) ﬂoxed mice, PRX1-Cre (FVB/N), OSX-Cre
(FVB/N) transgenic mice and ROSA26 mT/mG (FVB/N) reporter
mice have been previously described (Schipani et al., 2001; Gruber
et al., 2007; Haase et al., 2001; Logan et al., 2002; Rankin et al.,
2012). For all studies, cre-positive heterozygous ﬂoxed mice and
cre-negative homozygous ﬂoxed mice, respectively, were used as
controls. We found that the PRX1-Cre or OSX-Cre transgenes per se
did not affect any of the phenotypes described in this paper.
Generation of mT/mG mice has been previously described
(Muzumdar et al., 2007). Of note, though in the same genetic
background (FVB/N), in the study we strictly compared only
mutant and control littermates. Moreover, at least three mutants
and three controls were analyzed in each assay.
All procedures involving mice were performed in accordance
with the NIH guidelines for use and care of live animals, and were
approved by the Indiana University Institutional Animal Care and
Use Committee (IACUC).
Growth curve, whole mount Alizarin Red S/Alcian Blue staining,
routine histology, PAS staining, immunohistochemistry, in situ
hybridization, TUNEL, Oil Red O staining, safranin-O staining and
PCNA assay
Mice were weighed and measured at birth, p7, p14 and p21 to
generate weight and growth curves, respectively. Whole mount
Alizarin Red S/Alcian Blue staining was performed at birth as
previously described (Provot et al., 2007). For light microscopy,
tissues from E10.5, E12.5, E13.5, E14.5, E15.5, E17.5 (delivered by
cesarean section), newborn, p5, p17–p24 and 4 months were ﬁxed
in 4% Paraformaldehyde (PFA)/Phosphate Buffer Saline (PBS) (pH
7.4) for 48 h at 4 1C, and then stored in 70% ethanol at 4 1C.
Newborn and postnatal specimens were decalciﬁed in 20% Ethy-
lenediaminetetraacetic acid (EDTA) pH 7.5 at 4 1C for up to 10 days.
Parafﬁn blocks were prepared by standard histological procedures.
Sections (5–6 mm thick) were cut from several levels of the block,
and stained with Hematoxylin and Eosin.
For immunohistochemistry detection, parafﬁn sections from
forelimbs of E10.5, E12.5, E13.5 and E15.5 mice embryos were
treated with sodium citrate buffer pH 6 at 95 1C for 10 min. Sections
were then incubated with the following primary antibodies: VHL at
1:100 (BD 556347, BD Biosciences, San Jose, CA, USA), HIF-1α at a
1:100 (MAB1935, R&D Systems, Inc., Minneapolis, MN, USA) or HIF-
2α at a 1:100 (NB100-122, Novus Biologicals, LLC, Littleton, CO,
USA) overnight at 4 1C. After incubation with the appropriate
biotinylated secondary antibodies rabbit-anti-mouse (E 0413, Dako
North America Inc., Carpinteria, CA, USA) or swine-anti-rabbit
(E 0431, Dako North America Inc., Carpinteria, CA, USA), detection
of the binding was carried out using the labeled streptavidin biotin
(TSA) system following manufacturer's instructions (Perkin Elmer,
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Shelton CT, USA). Negative controls have been performed by
omitting the primary antibody.
in situ hybridizations were performed on parafﬁn sections from
hindlimbs and forelimbs of E13.5, E14.5, E15.5, p5 and p17 mice using
complementary 35S-labeled riboprobes, as previously described
(Provot et al., 2007).
For PAS staining, parafﬁn sections from hindlimbs of newborn
mice were stained using a PAS staining kit (Dako North America
Inc., Carpinteria, CA, USA) according to the manufacturer's
conditions.
TUNEL assay was performed on parafﬁn sections from hin-
dlimbs of E15.5 and p17-p21 mice using an “in situ cell death
detection” Kit (Roche Diagnostic, Mannheim, Germany). Sections
were permeabilized with 0.1% TritonX100 in 0.1% sodium citrate;
TUNEL assay was then carried on according to manufacturer's
instructions.
Oil Red O staining was performed on liver ﬁxed frozen sections
at p17. Sections were incubated in 0.5% Oil Red O solution (Sigma
Aldrich, St Louis, MO, USA) for 10 min, counterstained with
hematoxylin/acetic water for 1 min and coverslipped with aqu-
eous mounting medium (Vector Laboratories, Burlingame,
CA, USA).
For safranin-O staining, parafﬁn sections from forelimbs of
E12.5, E13.5, E14.5 and E15.5 embryos were stained with safra-
nin-O/fast green according to standard protocols (Ivkovic et al.,
2003).
PCNA assay was performed on parafﬁn sections from hindlimbs
of p18 mice using the PCNA Invitrogen Kit (Invitrogen Corporation,
Frederick, MD, USA), according to manufacturer's instructions.
BrdU incorporation
E15.5 pregnant mice were injected intraperitoneally with
100 μg BrdU/12 μg FdU per gram body weight 2 h prior to
sacriﬁce. After sacriﬁce, embryo hindlimbs were dissected, ﬁxed,
and embedded in parafﬁn, and longitudinal sections across the
tibia and femur were obtained. To identify actively proliferating
cells, nuclei that had incorporated BrdU were detected using a
Zymed BrdU immunostaining kit (Invitrogen Corporation, Freder-
ick, MD, USA). Both total number of cells and BrdU-positive cells
where manually counted in the Round Proliferative Layer (RPL)
and in the Columnar Proliferative Layer (CPL) of the developing
growth plates; proliferative rates were then calculated as number
of BrdU-positive cells divided by total number of cells.
Cryosections
Hindlimbs, spines and livers were dissected from E15.5, p3 and
p17 specimens, ﬁxed in 4% PFA/PBS at 4 1C for 48 h and then stored
in 70% ethanol at 4 1C. Postnatal specimens were decalciﬁed in 20%
EDTA pH 7.5 at 4 1C for up to 10 days. All the samples were
subsequently placed in 30% Sucrose/PBS overnight and then
embedded in optimum cutting temperature (OCT) embedding
medium. Samples were sectioned at a thickness of 10 mm using a
Leica cryostat. Sections were stored at 80 1C for later use.
Image acquisition
Images were acquired with Eclipse E800 (Nikon, Brighton, MI,
USA). Additional images were captured with a Leica DM LB
compound microscope (Leica Microsystems Inc., Buffalo Grove,
IL, USA). For ﬂuorescent images, frozen sections were dehydrated
at RT overnight, rinsed in distilled water for 10 min and then
overlayed with coverslips onto Vectashield Hard Set mounting
medium with 4ʹ,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Burlingame, CA, USA). Photos were taken using ﬁlters
for Red Fluorescent Protein (RFP), ﬂuorescein isothiocyanate (FITC)
and DAPI.
Transmission Electron Microscopy (TEM) and Toluidine Blue staining
Growth plates were cleared completely of surrounding soft
tissues, ﬁxed in EM ﬁxative (2.5% glutaraldehyde, 2.0% PFA, 0.025%
calcium chloride in a 0.1 M sodium cacodylate buffer [pH 7.4]), and
processed for EM. Two sets of consecutive sections were prepared:
1 μm sections stained with Toluidine Blue (5 min) to visualize the
tissue morphology; 0.3 μm sections that were placed on top of
grids for EM analysis. Samples were examined with a Phillips 301
Transmission Electron Microscope and digital images were cap-
tured using an AMT (Advanced Microscopy Techniques) CCD
camera at magniﬁcations ranging from 4500 to 19,500.
X-Rays
Hindlimbs and forelimbs were analyzed by radiography, using
an XPERT 80- L Cabinet X-ray System (Kevex-90 Kv) (Kubtec
X-Ray, Milford, CT, USA). Mice were imaged in a prone position
at p21 using 2.7 magniﬁcation for CNTRL mice and 6.6
magniﬁcation for VHL, HIF1 and VHL-HIF1 mice. The images were
acquired through Digicom NC software (Kubtec X-Ray, Milford,
CT, USA).
Cell isolation and culture
Primary chondrocytes were isolated from newborn growth
plates of VHL and CNTRL mice, respectively and cultured as
described (Aro et al., 2012). Deletion of Vhlh was conﬁrmed by
PCR analysis of the genomic DNA extracted from chondrocytes in
culture, as previously reported (Rankin et al., 2012).
Moreover, primary chondrocyte from newborn VHLf/f growth
plates were also isolated for adenovirus infection (Aro et al., 2012).
On day 1 post-plating, adherent VHLf/f chondrocytes were infected
with adenovirus containing either β-galactosidase or cre-recom-
binase (Vector Biolabs, Philadelphia, PA, USA) to generate wild-
type chondrocytes or VHL null cells.
All cells were incubated at 5% CO2 under humidiﬁed atmo-
sphere and media were changed every 2–3 days prior to collection.
Photos of cultured cells were taken with a Leica EC3 camera
(Leica Microsystems Ltd., Switzerland).
dsDNA quantiﬁcation: PicoGreen assay
Cells were rinsed twice with sterile, cold PBS (Cellgro, Media-
tech, Inc., Manassas, VA, USA) prior to addition of 1 mL diluted
lysis buffer, provided in Quant-iT PicoGreen dsDNA Assay kit
(P7589, Life Technologies, Grand Island, NY, USA). Plates were
wrapped in aluminum foil and placed at 80 oC overnight at
minimum. Plates were thawed at room temperature; samples
were vigorously triturated individually and transferred to DNase-
free microcentrifuge tubes. Samples and standards were loaded
onto black 96-well plates. PicoGreen ﬂuorescent nucleic acid stain
(from kit) was added and plates were incubated at room tempera-
ture, protected from light, for 5 min. Sample ﬂuorescence was
measured using the Synergy Mx microplate reader (BioTek,
Winooski, VT, USA) with an excitation wavelength of 480 nm
and emission wavelength of 520 nm.
Western blotting
For protein extraction, cells were lysed in buffer containing
sodium chloride, Tris, glycerol, Nonidet P-40 (Sigma Aldrich, St
Louis, MO, USA), EDTA, and protease inhibitors (Roche Diagnostic,
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Mannheim, Germany). Bicinchoninic acid assay was performed for
protein determination (Thermo Scientiﬁc, Rockford, Il, USA). Sam-
ples were analyzed by 10% SDS-PAGE gels (Bio-Rad Laboratories,
Hercules, CA, USA) and subsequently transferred to Polyvinylidene
ﬂuoride (PVDF) membrane utilizing the BioRad Criterion system.
Membranes were blocked in 5% milk in Tris-Buffered Saline with
Tween 20 (TBST) and incubated in 5% milk with TBST at 4 1C
overnight with the following primary antibodies: HIF-1α (NB 100-
479, Novus Biologicals, Littlelton, CO, USA) at 1:1000, HIF-2α
(AF2997, R&D Systems, Inc., Minneapolis, MN, USA) at 1:200, BiP
(3177S, Cell Signaling Technology, Inc., Danvers, MA, USA) at
1:1000 or p53 (VP-P952, Vector Laboratories, Inc., Burlingame,
CA, USA) at 1:500. The membranes were then incubated with
corresponding HRP-conjugated secondary antibodies goat-anti-
rabbit (Cell Signaling Technology, Inc., Danvers, MA, USA) or
donkey-anti-goat (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) at 1:2000 for 1 h in 5% milk with TBST. The blots were then
incubated in Amersham ECL Plus Western Blotting System (GE
Healthcare Biosciences, Pittsburgh, PA, USA), and chemilumines-
cent bands were visualized via the Image Quant LAS-4000 Fuji
imaging system (Fujiﬁlm Life Science, Tokyo, Japan). Quantiﬁcation
was performed using Image-J software (NIH). α-Tubulin antibody
(Cell Signaling Technology, Inc., Danvers, MA, USA) was used to
normalize protein amount.
Statistical analysis
Histograms are represented as the mean of the replicates 7SD.
Statistical differences were analyzed using the Student's t test.
Differences with a p-valueo0.05 were considered as statistically
signiﬁcant.
Results
Generation of mice lacking VHL in mesenchymal progenitors of the
limb bud
In order to deﬁne the role of VHL in the mesenchymal cells of
the limb bud, we conditionally inactivated VHL in cells expressing
cre-recombinase under the control of a PRX1 enhancer (PRX1-Cre).
For this purpose, mice homozygous for the Vhlh conditional alleles
(2-loxP) were crossed with PRX1-Cre mice to generate PRX1-Cre;
VHLf/f mutant (VHL) mice and PRX1-Cre;VHLf/þ or VHLf/f control
(CNTRL) mice.
Of note, PRX1-Cre;VHLf/þ and VHLf/f mice were phenotypically
identical, therefore for the purpose of this study they were used
indistinctly.
PRX1-Cre mediates efﬁcient cre-recombinase activity in
mesenchymal progenitors that differentiate both into cartilage
and bone, and into the soft tissue surrounding the cartilaginous
primordia (Logan et al., 2002; Hilton et al., 2008). The expression
of PRX1-Cre in cartilage and in the surrounding soft tissues was
conﬁrmed using mT/mG reporter mice (mTmG) (Muzumdar et al.,
2007). These mice have loxP sites on either side of a membrane-
targeted tandem dimer Tomato (mT) cassette, and express red
ﬂuorescence in all tissues. When bred to PRX1-Cre mice (PRX-
mTmG), the mT cassette is deleted, allowing expression of the
membrane-targeted EGFP (mG) cassette located downstream, in
the tissues where cre is active. In E15.5 PRX-mTmG mice, both
growth plate and surrounding soft tissues including the perichon-
drium displayed a positive EGFP signal, concomitant with the loss
of the red ﬂuorescent signal, indicating a high level of cre activity
at these sites (Fig. 1).
The VHL conditional allele contains 2-loxP sites ﬂanking the
Vhlh promoter and exon 1 (Haase et al., 2001). Recombination of
the VHL conditional allele in VHL chondrocytes was conﬁrmed by
genomic PCR analysis for the recombined (1-loxP) allele
(Supplemental Fig. 1, Panel A).
As predicted by the current model, an increased accumulation
of both HIF-1α and HIF-2α proteins was observed by Western blot
analysis of whole protein lysate extracted from VHL chondrocytes
when compared to CNTRL (Supplemental Fig. 1, Panel B). This
accumulation was conﬁrmed at the nuclear level by immunohis-
tochemistry (IHC) on histological sections of E15.5 mutant and
control growth plates (Supplemental Fig. 1, Panel C).
Moreover, in agreement with these ﬁndings, expression of
Vascular Endothelial Growth Factor (VEGF) mRNA, a classical
downstream target of both HIF-1α and HIF-2α (Maes et al.,
2012), was considerably augmented throughout the proliferative
zone of the mutant growth plates when compared to CNTRL
(Supplemental Fig. 1, Panel D). VEGF is an important regulator of
angiogenesis in endochondral bone development, and it is also a
chondrocyte survival factor (Maes et al., 2002; Zelzer et al., 2004).
Physiologically, VEGF mRNA is expressed both in hypertrophic
chondrocytes, and, though at lower levels, in the inner portion of
the proliferative zone, i.e., in the hypoxic region of the developing
growth plate (Maes et al., 2002; Zelzer et al., 2004).
Last, Transmission Electron Microscopy analysis and Toluidine
Blue staining of chondrocytes in vivo revealed the presence in the
mutant cells of lipid droplets and glycogen accumulation, which
are two hallmarks of VHL null specimens (Rankin et al., 2009)
(Supplemental Fig. 1, Panel E: a and b, c and d). Periodic Acid Schiff
(PAS) staining conﬁrmed the accumulation of glycogen in mutant
chondrocytes (Supplemental Fig. 1, Panel F).
Taken together, these ﬁndings provide clear evidence that VHL
was efﬁciently deleted and HIF-1α and HIF-2α were signiﬁcantly
stabilized in mutant growth plate chondrocytes.
Loss of VHL in mesenchymal progenitors of the limb bud generates
shorter and developmentally delayed fetal bones by impairing
proliferation of chondrocytes and by delaying their terminal
differentiation
Mice with loss of VHL in limb bud mesenchyme were born with
the expected mendelian frequency. Whole mount Alizarin Red S/
Alcian Blue staining performed at birth showed that, whereas
overall body size was similar (Fig. 2a and b), long bones were
shorter, thinner and deformed in VHL mice in comparison to
CNTRL (Fig. 2c–f), Of note, no obvious patterning defect was
detectable in mutants (Fig. 2a and b).
The PRX1-Cre transgenic mouse expresses cre-recombinase at
high level in the limb bud mesenchyme starting from E9.5, i.e.,
before mesenchymal condensations form (Logan et al., 2002). Loss
of HIF-1α in mesenchymal progenitors delays early chondrogen-
esis and joint development (Provot et al., 2007). We thus asked the
question whether loss of VHL affects these two processes.
IHC provided convincing evidence that VHL protein is
expressed in wild type limb bud mesenchyme at E10.5, and that
we had successfully knocked out VHL in mesenchymal cells at this
early stage of development (Supplemental Fig. 2, Panel A: a and b).
However, safranin-O staining of E12.5 forelimb autopods
indicated that loss of VHL did not accelerate differentiation of
mesenchymal progenitors into chondrocytes (Supplemental Fig. 2,
Panel B: a and b).
Consistent with this conclusion, at E13.5 both mutant and
control chondrocytes in the autopod showed similar morphology,
comparable glycosaminoglycans content (Supplemental Fig. 2,
Panel B: c and d), and equivalent levels of expression of Sox9
and type II collagen (Col2a1) mRNAs (Supplemental Fig. 4, Panel C;
a and b, c and d). Sox9 is the “master” transcription factor of
chondrogenesis, and its mRNA is expressed in proliferative
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chondrocytes but not in hypertrophic cells (Provot and Schipani,
2005); Col2a1 mRNA is a classical chondrogenic marker.
Notably, loss of VHL did not affect the process of joint
segmentation either, as suggested by the analysis of Growth
Differentiation Factor 5 (GDF5) mRNA expression (Supplemental
Fig. 2, Panel C: e and f). GDF5 is one of the earliest markers of joint
speciﬁcation, and it can be detected before interzones become
histologically evident (Storm and Kingsley, 1996; Merino et al.,
1999).
Differently from early chondrogenesis, the subsequent steps of
endochondral bone development were severely altered by loss of
VHL. In particular, E13.5 mutant stylopods were already consider-
ably smaller than controls, as indicated by H&E staining and by
Col2a1 mRNA expression (Fig. 3, Panel A: a–d). Moreover,
chondrocyte terminal differentiation was severely delayed in
VHL specimens in comparison to CNTRL, as shown by the unin-
terrupted expression of Sox9 mRNA (Fig. 3, Panel A: e and f), the
smaller domain of type X collagen (Col10a1) mRNA (Fig. 3, Panel
A: g and h), and the lack of osteopontin (SPP1) mRNA (Fig. 3, Panel
A: i and j). Col10a1 is a classical marker of hypertrophic chon-
drocytes, and its mRNA is already detectable immediately before
hypertrophy occurs; it is then down regulated in the late hyper-
trophic chondrocytes located at the border with the primary
spongiosa (Provot and Schipani, 2005). SPP1 mRNA is produced
by late hypertrophic cells (Provot and Schipani, 2005).
In addition, data collected by routine histology (Supplemental
Fig. 3a and b) and by in situ hybridization analysis of E14.5
stylopods, namely persistence of Col2a1 mRNA in the center of
Fig. 1. PRX1-Cre expression in fetal growth plate. (a–f) Detection of ﬂuorescence in frozen sections of tibias isolated from E15.5 mTmG (upper panels) and PRX-mTmG (lower
panels) mice, respectively. The following abbreviations are used: mT, Membrane-targeted tandem dimer Tomato (a and b); mG, Membrane-targeted EGFP (c and d); DAPI,
40 ,6-diamidino-2-phenylindole counterstain (blue nuclei) (e and f). (Bar¼250 μm).
Fig. 2. Macroscopic appearance of VHL mice at birth. (a and b) Whole mount Alizarin Red S/Alcian Blue staining of CNTRL (a) and VHL (b) newborns mice. (Bar¼50 mm).
(c–f) Whole mount Alizarin Red S/Alcian Blue staining of forelimbs (upper panels) and hindlimbs (lower panels) of CNTRL (c and e) and VHL (d and f) mice. The arrow in
(d) points at the radius deformity. (Bar¼50 mm).
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the cartilaginous element and presence of one single domain of
Col10a1 mRNA in mutant elements (Supplemental Fig. 3c and d, e
and f), further supported the notion that at this developmental
stage mutant hypertrophic chondrocytes, differently from con-
trols, had not yet transitioned into late hypertrophic cells, which
do not express Col2a1 mRNA and display lower amounts of
Col10a1 mRNA.
Last, consistent with the hypothesis that loss of VHL delays
endochondral bone development, formation of the bone marrow
cavity was delayed in mutant specimens in comparison to controls
(Fig. 3, Panel B: a and b), as conﬁrmed by the larger domains of
Col2a1 and Col10a1 mRNA expression in E15.5 mutant stylopods
(Fig. 3, Panel B: c and d, e and f), and by the persistence in mutants
of a safranin-O positive matrix in a region that was already
occupied by bone marrow in control specimens (Fig. 3, Panel B:
g and h).
In line with our previous ﬁndings obtained in mutant mice in
which VHL had been deleted in cells already committed to the
chondrocyte lineage (Pfander et al., 2004), a signiﬁcant impair-
ment of chondrocyte proliferation in both round proliferative and
columnar layers was also detected in mutant fetal growth plates,
as indicated by BrdU analysis (Fig. 4, Panel A). Moreover, as
previously reported (Pfander et al., 2004), mutant chondrocytes
in the round proliferating zone of the fetal growth plate were
abnormally enlarged with a higher cytoplasm to nucleus ratio
(Fig. 4, Panel B).
In addition to their shortening, loss of VHL in limb bud
mesenchyme caused deformities of the forelimb zeugopod as
shown by H&E (Fig. 5, Panel A: a and c), and by in situ hybridiza-
tion analysis for Col2a1 and Col10a1 mRNAs (Fig. 5, Panel A: b, d
and e) of 15.5 specimens. Of note, these deformities, which were
still detectable postnatally by X-Rays (Fig. 5, Panel B), affected the
same bone at the same location, consistently displayed the same
shape, and had full penetrance and expressivity (data not shown).
Collectively, our ﬁndings demonstrate that loss of VHL in limb
bud mesenchyme does not alter either chondrogenic differentia-
tion of mesenchymal progenitors or joint development, but it
impairs proliferation of chondrocytes, delays their terminal differ-
entiation and results in bone deformities at speciﬁc sites.
Loss of VHL in mesenchymal progenitors of the limb bud causes
massive chondrocyte death associated to complete growth arrest and
lack of the secondary ossiﬁcation center in the postnatal growth plate
After birth, mutant mice became overall smaller than control
littermates (Fig. 6, Panel A and B: a); they lost weight (Fig. 6, Panel
B: b), and eventually died at 4 weeks of age for a cause yet to be
identiﬁed.
Notably, at postnatal time points, loss of VHL blocked the
formation of the secondary ossiﬁcation center, and led to the
complete disappearance of both the columnar and the hyper-
trophic layers (Fig. 7a–d). This phenotype was likely the result of
the severe impairment of proliferation and the profound delay of
terminal differentiation observed at earlier time points. Curiously,
islets of hypertrophic cartilage persisted within the bone marrow
(Fig. 7b and d), which suggests that a very disorganized cartilage-
to-bone transition occurred in VHL mutants.
Interestingly, Col2a1 mRNA expression was dramatically down
regulated in the round proliferative chondrocyte layer of the
postnatal growth plate (Fig. 7e and f). This somehow unusual
ﬁnding was not due to either chondrocyte hypertrophy or to
chondrocyte transdifferentiation into ﬁbroblasts, as mutant chon-
drocytes did not express either Col10a1 mRNA (data not shown) or
type I collagen (Col1a1) mRNA (Fig. 7g and h), respectively, but it
was most likely the consequence of massive cell death (Fig. 7i and j).
Cell death was associated to complete arrest of cell proliferation, as
indicated by PCNA staining (Fig. 7k and l). Curiously, no sign of
Fig. 3. Prenatal growth plate phenotype in VHL mice. (A) Delayed terminal differentiation. (a and b) H&E staining of E13.5 humerus from CNTRL (a) and VHL (b) specimens.
(Bar¼250 μm). (c–j) in situ hybridization for detection of Col2a1 (c and d), Sox9 (e and f), Col10a1 (g and h) and SPP1 (i and j) mRNAs in E13.5 CNTRL (upper row) and VHL
(lower row) specimens. Dark-ﬁeld images are shown. (Bar¼250 μm). (B) Delay of bone marrow cavity formation. (a and b) H&E staining of E15.5 humerus isolated from
CNTRL (a) and VHL (b) mice. (Bar¼250 μm). (c–f) in situ hybridization for detection of Col2a1 (c and d) and Col10a1 (e and f) mRNAs in E15.5 CNTRL (upper row) and VHL
(lower row) samples. Bright-ﬁeld images are shown. (Bar¼250 μm). (g and h) Safranin-O staining of E15.5 humerus isolated from CNTRL (g) and VHL (h) mice.
(Bar¼250 μm).
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chondrocyte death had been detected at prenatal time points (data
not shown).
Postnatal VHL mutants also displayed a smaller axial skeleton
(Fig. 6, Panel A) and, histologically, a very modest delay of
replacement of cartilage by bone in the vertebral bodies, though
their overall architecture was normal (Supplemental Fig. 4, Panel A).
This quite mild phenotype was not due to ectopic expression of
the cre in the axial skeleton, as shown by the use of the mTmG
reporter (Supplemental Fig. 4, Panel B). The lack of ectopic
expression of cre in the vertebral bodies is consistent with the
observation that, differently from the postnatal time points, the
overall size of the axial skeleton of VHL mutants at birth was
normal, as shown by whole mount Alizarin Red S/Alcian Blue
staining (Fig. 2a and b). Thus, the postnatal axial skeleton pheno-
type of VHL mutants was most likely contributed by systemic
factors.
Along these lines, mutant mice displayed a liver phenotype
characterized by the presence of hemorrhagic cysts (Supplemental
Fig. 5, Panel A: a–c), angiectases, and abnormal proliferation of
ﬁbroblastoid cells, which were initially located in close proximity
to blood vessels, but eventually invaded and replaced the liver
parenchyma (Supplemental Fig. 5, Panel A: d–g). Moreover, con-
sistent with the deletion of VHL, we observed a unique accumula-
tion of lipids in the mutant hepatocytes by Oil Red O staining
(Supplemental Fig. 5, Panel A: h and i). All in all, these lesions were
reminiscent of the hemangioblastomas that develop in liver upon
speciﬁc deletion of VHL in hepatocytes (Haase et al., 2001). Tissue
surveys of the PRX-mTmG mice revealed ectopic activity of cre-
recombinase in hepatocytes (Supplemental Fig. 5, Panel B), which,
to our knowledge, has not previously been reported.
Importantly, this liver phenotype was not present at birth
(Supplemental Fig. 5, Panel C), but it developed postnatally and
could explain, at least in part, the overall decrease of body size and
the premature death of VHL mutants.
Taken together, our data indicate that the dramatic decrease of
body size and weight of VHL mutant mice postnatally is most
likely the consequence of systemic factors including a potential
liver failure. However, and most importantly, the postnatal limb
phenotype of VHL mice appears to be very speciﬁc and not
contributed by systemic factors for two main reasons: ﬁrst,
differently from the long bones, the postnatal vertebral bodies in
VHL mutants are histologically very similar to controls, except for
an extremely mild delay of replacement of cartilage by bone;
second, no limb abnormalities have been reported upon speciﬁc
deletion of VHL in hepatocytes (Haase et al., 2001).
Loss of VHL in mesenchymal progenitors of the limb bud results in a
severe bone phenotype, which, however, does not signiﬁcantly
contribute to the growth plate abnormalities
Since the PRX1-Cre transgene is expressed in the osteochon-
droprogenitors that give origin not only to cartilage but also to
bone (Logan et al., 2002; Hilton et al., 2008), to be thorough we
attempted to study trabecular bone in mutant and control tibias
around p21 by routine histology, despite the premature death of
the mutant mice. This analysis revealed a dramatic increase of
trabecular bone in mutant specimens as shown by X-rays and
routine histology (Fig. 8). This excessive trabecularization was
associated to dilated bone marrow blood vessels and to the
presence of a stromal cell population in between the bony
trabeculae with only a few islets of hematopoietic cells (Fig. 8,
Panel B: b). The premature demise of the VHL mutant mice around
p28 precluded us from pursuing a further and extensive charac-
terization of their bone phenotype. Nonetheless, the ﬁnding
conﬁrmed our previous data obtained in mutant mice in which
we had speciﬁcally deleted VHL in cells of the osteoblast lineage at
different stages of differentiation (Rankin et al., 2012; Wang et al.,
2007).
Fig. 4. Impaired proliferation and abnormal morphology of VHL chondrocytes. (A) Chondrocyte proliferation rate in fetal VHL growth plates. (a–c) BrdU assay of E15.5
proximal epiphyses of tibia isolated from CNTRL (a) and VHL (b) mice; quantiﬁcation of the data is shown in (c) (*p-valueo0.05 and ***p-valueo0.001). The lines in (a and
b) highlight the growth plate and separate the RPL from the CPL. The following abbreviations are used: RPL, Round Proliferative Layer; CPL, Columnar Proliferative Layer.
(Bar¼250 μm). (B) “Atypical” chondrocytes in absence of VHL. (a and b) H&E staining of E17.5 distal humerus in CNTRL (a) and VHL (b) samples. The arrows in (b) point at
atypical chondrocytes. (Bar¼250 μm).
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We next asked whether the postnatal growth plate abnormal-
ities observed in VHL mutant mice, and in particular the disorga-
nized transition from cartilage to bone, was somehow the
consequence of their bone phenotype. To speciﬁcally address this
question, we conditionally knocked out VHL in cells of the
osteoblast lineage using OSTERIX-Cre transgenic mice (OSX-Cre)
(Rodda and McMahon, 2006); we thus generated mutants (OSX-
VHLf/f), cre-positive heterozygous ﬂoxed (OSX-VHLf/þ) and cre-
negative homozygous ﬂoxed (VHLf/f) controls. We then analyzed
the developing growth plate at multiple time points from E15.5 to
4 months of age in all experimental groups.
As expected, mutant mice lacking VHL in cells of the osteoblast
lineage dysplayed a dramatic accumulation of trabecular bone;
conversely, their growth plate phenotype was extremely modest
Fig. 5. Radius deformity in VHL mice. (A) Histological appearance of the radius deformity. (a and c) H&E staining of histological sections of E15.5 forelimb isolated from
CNTRL (a) and VHL (c) mice. (Bar¼250 μm). (b, d, and e) in situ hybridization for detection of Col2a1 (b and d) and Col10a1 (e) mRNAs in CNTRL (b) and VHL (d and e)
specimens. Bright-ﬁeld pictures are shown. The arrows in (c–e) indicate the deformity of the radius. (Bar¼250 μm). (B) Postnatal persistence of the radius deformity.
(a and b) X-rays pictures of p21 forelimb isolated from CNTRL (a) and VHL (b) mice. The arrow in (b) indicates the deformity of the radius. (Bar¼1 cm).
Fig. 6. Postnatal growth arrest of VHL mice. (A) Macroscopic appearance of VHL mice. (a and b) Photograph of p21 CNTRL (a) and VHL (b) mice. (B) Growth curve of VHL
mice. (a and b) Length (a) and weight (b) curves of CNTRL and VHL mice from p0 to p21. (*p-valueo0.05 and **p-valueo0.01).
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and mainly characterized by a quite mild and very transient delay
of terminal differentiation (Supplemental Fig. 6), which is consis-
tent with the notion that in OSX-Cre transgenic mice, cre is also
expressed in hypertrophic chondrocytes, though at a low level
(Kobayashi et al., 2008).
In light of these ﬁndings, we can thus conclude that mutant
mice lacking VHL in limb bud mesenchyme exhibit, as expected, a
dramatic bone phenotype, which most likely is not the cause of
their severe growth plate abnormalities.
Of note, since in the PRX1-Cre transgenic mouse, cre is not
active in the endothelium (Logan et al., 2002; Eshkar-Oren et al.,
2009), it is highly unlikely that any of the histological features
dysplayed by the VHL mutant mice in either cartilage or bone is a
consequence of deletion of VHL in endothelial cells.
Loss of HIF-2α in VHL deﬁcient mesenchymal progenitors of the limb
bud accelerates the replacement of cartilage by bone
In order to identify a possible role for HIF-1α in mediating at
least in part the dramatic growth plate phenotype secondary to
loss of VHL, we generated mice lacking both VHL and HIF-1α (VHL-
HIF1) in limb bud mesenchyme. Notably, these double mutant
mice had a dramatically abnormal postnatal growth plate that was
virtually indistinguishable from the mutant growth plate of mice
lacking exclusively HIF-1α (Supplemental Fig. 7). This ﬁnding
shows that HIF-1α is indeed epistatic to VHL, and it thus
conﬁrmed what we had previously documented in a mutant
model in which both proteins had been conditionally deleted by
using a cre-recombinase driven by a fragment of the Col2a1
promoter (Pfander et al., 2004).
Since also HIF-2α is stabilized in VHL mutant chondrocytes
(Supplemental Fig. 1, Panel B: a and c) we decided to study a possible
role of this transcription factor in mediating some of the effects
secondary to loss of VHL in limb bud mesenchyme. For this purpose,
we generated mice lacking both VHL and HIF-2α in limb bud
mesenchyme (VHL-HIF2). Mice were born with the expected mende-
lian frequency and they were viable, but they also died around p28
(data not shown).
Loss of HIF-2α did not correct the delayed hypertrophic differ-
entiation observed in the VHL mutant growth plate, as indicated by
routine histology and by in situ hybridization analysis for Col10a1
mRNA expression (Fig. 9, Panel A: a and b, c and d). In addition, mice
lacking both VHL and HIF-2α still displayed impaired chondrocyte
proliferation, and massive postnatal cell death (Fig. 9, Panel B and
Fig. 7. Postnatal growth plate collapse and massive cell death in VHL mice. (a–d) H&E staining of p18 distal femur in CNTRL (a) and VHL (b) specimens. Higher respective
magniﬁcation is shown in panels (c and d). The arrow in (d) indicates the persistence of hypertrophic cartilage within the bone marrow. (Bar¼250 μm). (e–h) in situ
hybridization for detection of Col2a1 (e and f) and Col1a1 (g and h) mRNAs in CNTRL (e and g) and in VHL (f and h) p18 distal femur specimens. Dark-ﬁelds are shown.
(Bar¼250 μm). (i and j) TUNEL assay in p18 distal femur of CNTRL (i) and VHL (j) specimens. The lines on each panel highlight the growth plate. (Bar¼250 μm). (k and l)
PCNA staining of histological sections of p18 distal epiphyses of femur isolated from CNTRL (k) and VHL (l) mice. The lines on each panel highlight the growth plate.
(Bar¼250 μm).
L. Mangiavini et al. / Developmental Biology 393 (2014) 124–136132
data not shown). Moreover, they had no histological evidence of
formation of the secondary ossiﬁcation center (data not shown).
However, loss of HIF-2α rescued the timely formation of the bone
marrow cavity (Fig. 9, Panel C) and accelerated the replacement of
cartilage by bone with, consequently, complete disappearance of the
hypertrophic layer at an even earlier time point than in VHL single
mutants, as indicated by routine histology and by in situ hybridiza-
tion analysis for Col10a1 mRNA expression (Fig. 9, Panel D: a, c, e, g
and b, d, f, h). This ﬁnding, which was somehow unexpected as loss
of HIF-2α in limb bud mesenchyme determines only a modest and
Fig. 8. Bone phenotype in VHL mice. (A) Radiological appearance of VHL hindlimbs. (a and b) X-rays pictures of p21 hindlimb isolated from CNTRL (a) and VHL (b) mice.
(Bar¼1 cm). (B) Histological appearance of VHL bone. (a and b) H&E staining of p17 tibias isolated from CNTRL (a) and VHL (b) mice. The arrow in (b) points at a dilated blood
vessel; the circle in (b) highlights stromal cells in between the bony trabeculae. (Bar¼250 μm). Please, note the presence of cartilaginous remnants in VHL bone, which could
be suggestive of impaired resorption.
Fig. 9. Growth plate phenotype of VHL-HIF2 mice. (A) Delayed terminal differentiation. (a and b). H&E staining of E13.5 humerus isolated from CNTRL (a) and VHL-HIF2
(b) mice. (Bar¼250 μm). (c and d) Detection of Col10a1 mRNA by in situ hybridization analysis of E13.5 humerus isolated from CNTRL (c) and VHL-HIF2 (d) mice. Bright-ﬁeld
images are shown. (Bar¼250 μm). (B) Postnatal massive cell death. (a and b) TUNEL assay of p21 distal femur and proximal tibia isolated from CNTRL (a) and VHL-HIF2
(b) mice, respectively. The lines on each panel deﬁne the joint limits. (Bar¼250 μm). (C) Partial rescue of bone marrow cavity formation. (a–d) H&E staining of E15.5 humerus
isolated from CNTRL (a), HIF2 (b), VHL (c) and VHL-HIF2 (d) mice. The rectangles on each panel outline the location of the putative bone marrow cavity. (Bar¼250 μm). Please
note the very modest delay of terminal differentiation in HIF-2 mice. (D) Premature disappearance of the hypertrophic layer. (a, c, e, and g) H&E staining of p5 distal growth
plate of humerus isolated from CNTRL (a), HIF2 (c), VHL (e) and VHL-HIF2 (g) mice. (Bar¼250 μm). (b, d, f, and h) Detection of Col10a1 mRNA by in situ hybridization analysis
of p5 distal growth plate of humerus isolated from CNTRL (b), HIF2 (d), VHL (f), VHL-HIF2 (h) mice. Dark-ﬁeld images are shown. (Bar¼250 μm).
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transient delay in chondrocyte terminal differentiation (Araldi et al.,
2011), suggests that HIF-2αmay indeed have a ﬁne tuning role at the
interface between cartilage and bone.
Loss of VHL impairs proliferation and increases accumulation of BiP
protein in chondrocytes in vitro
In order to start dissecting out the complex in vivo phenotype
of mutant growth plate lacking VHL, we performed a series of
in vitro analysis. For this purpose, we isolated chondrocytes from
VHLf/f newborn mice as described in “Materials and methods”. We
next infected them with either β-galactosidase or cre-recombinase
adenoviral constructs in order to obtain wild type (β-gal) and VHL
null (cre) chondrocytes, respectively.
Cell density was considerably decreased in VHL null chondro-
cyte cultures; in addition, morphology of mutant cells appeared to
be substantially different from controls, as VHL null chondrocytes
had lost the classical “cobblestone” appearance and had rather
assumed an elongated, ﬁbroblastoid shape (Fig. 10, Panel A).
Analysis of DNA accumulation by Picogreen assay conﬁrmed that
loss of VHL had signiﬁcantly impaired chondrocyte proliferation
in vitro (Fig. 10, Panel B) (Young and Kaelin, 2008).
An extensive literature has suggested a complex relationship
between the tumor suppressor gene p53 and VHL, which is often
context-dependent (Jung et al., 2013; Cameron et al., 2011; Essers
et al., 2014). Since the growth arrest observed in VHL mutant
chondrocytes could in principle be mediated by stabilization of
p53 in these cells, we analyzed accumulation of p53 protein in
whole cell lysate of newborn chondrocytes isolated from mutant
and control growth plate chondrocytes. Interestingly, p53 protein
was not detectable in control chondrocytes, as also previously
reported by others (Zaman et al., 2007) and, more importantly, its
expression was not up regulated in mutant chondrocytes (data not
shown).
It has been reported that endoplasmic reticulum (ER) stress
halts chondrocyte proliferation and differentiation and causes
their death (Cameron et al., 2011; Malhotra and Kaufman, 2007;
Tsang et al., 2010; Yeung Tsang et al., 2014); moreover, VHL has
been recently localized in the ER (Kaelin, 2008; Schoenfeld et al.,
2001). We thus asked the question whether loss of VHL activates
the unfolded protein response (UPR) in chondrocytes in vitro. For
this purpose, we analyzed expression of the Binding immuglobulin
Protein (BiP or GRP78), which is a marker of UPR (Lai et al., 2007).
Notably, levels of BiP expression were signiﬁcantly higher in VHL
null chondrocytes when compared to controls (Fig. 10, Panel C),
which suggests that ER stress could be one of the pathogenetic
events involved in the generation of the complex growth plate
phenotype caused by loss of VHL in mesenchymal progenitors.
Discussion
In this study, we report the ﬁrst conditional knockout of VHL in
mesenchymal progenitors of the limb bud, i.e., in cells not yet
committed to the chondrocyte lineage. Deﬁciency of VHL in limb
bud mesenchyme does not alter the timely differentiation of
mesenchymal cells into chondrocytes. However, it causes struc-
tural collapse of the cartilaginous growth plate as a result of
impaired proliferation, delayed terminal differentiation and ecto-
pic death of chondrocytes. This phenotype is associated to delayed
replacement of cartilage by bone. Loss of HIF-2α fully rescues the
late formation of the bone marrow cavity in VHL mutant mice,
though it does not affect any other detectable abnormality of the
VHL mutant growth plates. Our ﬁndings demonstrate that VHL
regulates bone morphogenesis as its loss considerably alters size,
shape and overall development of the skeletal elements.
Interestingly, the growth plate phenotype of mutant mice
lacking VHL in limb bud mesenchyme is deﬁnitively more severe
than the one we reported upon deletion of VHL in already
differentiated chondrocytes (Pfander et al., 2004). Moreover, our
novel mouse model displays unique features, including a dramatic
delay of hypertrophy as well as a massive postnatal chondrocyte
death. We do not exactly know why the two mutant mice differ
from each other, but it is tempting to speculate that both the
diverse spatial and temporal distribution of the cre-recombinase
and the potential differences in the efﬁciency of deletion of the
ﬂoxed allele are factors that could contribute to generate the
phenotypic differences we detected between the two mutant lines.
The analysis of VHL mutant bones also revealed a series of
intriguing paradoxes.
In particular, a delay of terminal differentiation similar to the
one observed in VHL deﬁcient mice has also been described in
mice lacking HIF-1α either in limb bud mesenchyme (Provot et al.,
2007) or in chondrocytes (Schipani et al., 2001; Zelzer et al., 2004).
This apparent resemblance, however, is most likely the result of
profoundly different molecular and/or cellular mechanisms. Along
these lines, it is important to note that loss of HIF-1α in limb bud
mesenchyme delays differentiation of mesenchymal progenitors
into chondrocytes, and, thus, it is highly probable that this initial
delay of early chondrogenesis contributes to slow down hyper-
trophy. Conversely, VHL does not affect the initial steps of
chondrogenesis. In addition, loss of HIF-1α in both limb bud
mesenchyme and in chondrocytes causes a massive cell death
phenotype in the fetal growth plate that is not initially present in
the VHL mutants.
Though we yet do not know why chondrocytes lacking VHL
display a signiﬁcant delay of hypertrophy, however, in this study
we provide evidence that this phenotype is not due to stabilization
of HIF-2α, since it is not corrected by HIF-2α deletion.
Fig. 10. in vitro phenotype of chondrocytes lacking VHL. (A) Abnormal morphology of VHL null chondrocytes. (a and b) Microscopic pictures of wild type (β-gal) (a) and VHL
null (cre) (b) chondrocytes. (Bar¼250 μm). (B) Growth arrest of VHL null chondrocytes. Picogreen assays in wild type (β-gal) and VHL null (cre) chondrocytes.
(*p-valueo0.05). (C) Accumulation of BiP in absence of VHL. (a and b) Western blot analysis of BiP in protein lysate from wild type (β-gal) and VHL null (cre) chondrocytes.
α-Tubulin was used as a loading control. Quantiﬁcation of the data is shown in (b) (*p-valueo0.05).
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The impairment of chondrocyte proliferation and the growth
arrest we observed in VHL mutants is also paradoxical and
surprising since VHL is a tumor suppressor gene, but it is well in
agreement with previous ﬁndings by us and others (Pfander et al.,
2004; Young et al., 2008; Mack et al., 2003, 2005). In addition, it is
consistent with the notion that HIF-1α stabilization slows down
cell proliferation (Keith et al., 2011), probably as part of a complex
homeostatic response whose ultimate goal is likely to keep oxygen
consumption in check. Interestingly, however, VHL has been
reported to inhibit progression through the cell cycle in a HIF-
1α-independent fashion (Young et al., 2008). It is thus possible
that the decreased proliferation ﬁrst and the virtual growth arrest
later observed in VHL mutant growth plates could be the result of
either HIF-1α-dependent or HIF-1α-independent VHL functions.
Loss of VHL, delays blood vessel invasion and the formation of
both the primary and secondary ossiﬁcation centers. This is another
paradoxical ﬁnding since vascularization of the cartilage template,
which is a required step in endochondral bone development,
depends largely on VEGF, i.e., a classical downstream target of the
HIF signaling pathway (Maes et al., 2012). The delayed blood vessel
invasion is, however, consistent with the overall delay of chondro-
cyte hypertrophy observed in VHL mutant bones. Moreover, it
further highlights the intrinsic resistance of quiescent or prolifera-
tive cartilage to be invaded by blood vessels, despite increased
expression of VEGF (Pfander et al., 2004; Maes et al., 2010).
Along the line of paradoxical ﬁndings, postnatal VHL chondro-
cytes display a severe cell death phenotype despite the stabiliza-
tion of HIF-1α, which is a survival factor in the developing
growth plate.
Lastly, loss of HIF-2α in the context of VHL mutant mice
dramatically accelerates the replacement of cartilage by bone,
but loss of HIF-2α in limb bud mesenchyme causes a transient
and modest delay in hypertrophy mainly due to an impairment of
differentiation of hypertrophic chondrocytes into late hyper-
trophic cells (Araldi et al., 2011).
To this end, we do not have a full understanding of these
paradoxes; however, our in vitro ﬁndings suggest that ER stress may
be a contributing factor to the complex phenotype of VHL mutant
growth plates. Along these lines, it has been shown that ER stress is an
important pathogenetic event in some chondrodysplasias (Cameron
et al., 2011; Tsang et al., 2010; Yeung Tsang et al., 2014). Moreover, the
VHL protein has been associated to the ER (Kaelin, 2008; Schoenfeld
et al., 2001). In our study, we report, for the ﬁrst time to our
knowledge, that deletion of VHL leads, with yet unknown mechan-
isms, to accumulation of BiP, a classical marker of UPR.
Of note, it has been recently reported that VHL regulates Sox9
expression in pancreas (Puri et al., 2013). Moreover it is also
known that ectopic expression of Sox9 in growth plate causes
delayed terminal differentiation and cartilage vascularization
associated with reduced bone growth (Hattori et al., 2010; Kim
et al., 2011). Therefore, a role of Sox9 in mediating some of the
abnormal features we observe in VHL mutant growth plates
cannot be excluded at this stage of investigation.
In conclusion, we demonstrated that VHL plays an important
role in chondrocyte differentiation and survival; further studies will
be necessary to unveil the detailed molecular mechanisms that lead
to the severe abnormalities of endochondral bone development
observed in mutant mice lacking VHL in mesenchymal progenitors
of the limb bud.
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